Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve : A single-center, single-dose, randomized, open-label, 2-way crossover study under fasting conditions

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 3, 2010, Pages 116-123

  Almeida, Susana ^a,b   Filipe, Augusto ^a   Neves, Rita ^a   Desjardins, Isabelle ^c   Shink, Eric ^c   Castillo, Araceli ^d  

^a Tecnimede Group   (Portugal)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Anapharm Canada   (Canada)

^d Anapharm Europe SL   (Spain)

Author keywords

Acetylcholinesterase inhibitor; CAS 120014 06 4; Donepezil, bioequivalence, generic, pharmacokinetics; Truncated AUC

Indexed keywords

CAS 120014 06 4; DONEPEZIL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BIOEQUIVALENCE; BLOOD PRESSURE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG TOLERABILITY; EAR DISEASE; FEMALE; HEART RATE; HEMATOCRIT; HOT FLUSH; HUMAN; HYPERHIDROSIS; INNER EAR DISEASE; LEUKOCYTE COUNT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MOOD; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL STIFFNESS; NAUSEA; PAIN; PHYSICAL EXAMINATION; PLASMA; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SWELLING; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; TOOTH PAIN; TREMOR; VITAL SIGN;

EID: 77950600927     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296259     Document Type: Article

References (11)

1. Electronic Medicines Compendium (eMC). Datapharm Communications Ltd. [online]. [cited 2008/07/09]; available from: www.medicines.org.uk
2. Canadian Pharmacists Association, 2008. Compendium of Pharmaceuticals and Specialties, online version (e-CPS). [online]. 2008 [cited 2008/07/09]; available from: https:// www.e-therapeutics.ca/
3. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following oral doses. Br J Pharmacol 1998;46(Suppl 1):1-6.
4. Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolismand elimination of 14C-donepezil in healthy volunteers: A singledose study. Br J Pharmacol 1998;46(Suppl 1):19-24.
5. Xie Z, Liao Q, Xu X, Yao M, Wan J, Liu D. Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun Mass Spectrometry 2006;20:3193-8. (Pubitemid 44626781)
6. Park EJ, Lee HW, Ji HY, Kim HY, Lee MH, Park ES, et al. Hydrophilic interaction chromatography-tandem mass spectrometry of donepezil in human plasma: application to a pharmacokinetic study of donepezil in volunteers. Arch PharmRes 2008;31(9):1205-11.
7. Seltzer B. Donepezil: an update. Expert Opin Pharmacother 2007;8(7):1011-23.
8. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41(10):719-39.
9. Note For Guidance on the Investigation of Bioavailability and Bioequivalence. CPMP (Committee for Proprietary Medicinal Products), 2001.
10. Good Clinical Practice Consolidated Guideline. International Conference on Harmonisation, E6. 1996.
11. Guideline on the investigation of bioequivalence. Committee for Medicinal Products for Human Use (CHMP), Doc. Ref. CPMP/EWP/QWP/1401/98 Rev. 1, 2010.